13therapeutics
Private Company
Funding information not available
Overview
Founded in 2021, 13therapeutics is an early-stage biotech leveraging a peptide discovery platform to create new treatments for inflammatory conditions. The company's pipeline includes lead candidates like P13 and P7, targeting indications ranging from systemic inflammation to otitis media and noise-induced hearing loss. As a private, pre-revenue entity, it is in the research and development phase, building its scientific foundation and advancing programs toward clinical validation. Its success will hinge on translating its peptide platform into clinically effective therapies in competitive inflammatory markets.
Technology Platform
Platform for identifying, characterizing, and optimizing novel anti-inflammatory peptide therapeutics.
Opportunities
Risk Factors
Competitive Landscape
The anti-inflammatory drug market is highly competitive, dominated by large molecule biologics and small molecules. 13therapeutics competes with numerous biotechs and pharma companies, though its focus on peptide therapeutics for specific hearing-related inflammation may offer a differentiated niche. It must also compete for funding and talent within the broader biotech ecosystem.